These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 20065126)

  • 21. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease.
    Pinter MM; Rutgers AW; Hebenstreit E
    J Neural Transm (Vienna); 2000; 107(11):1307-23. PubMed ID: 11145006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
    Hauser RA; Olanow CW; Kieburtz KD; Pourcher E; Docu-Axelerad A; Lew M; Kozyolkin O; Neale A; Resburg C; Meya U; Kenney C; Bandak S
    Lancet Neurol; 2014 Aug; 13(8):767-76. PubMed ID: 25008546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical experience with pramipexole in the treatment of restless legs syndrome.
    Merlino G; Serafini A; Robiony F; Valente M; Gigli GL
    Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):225-35. PubMed ID: 18248314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study.
    Gunzler SA; Koudelka C; Carlson NE; Pavel M; Nutt JG
    Arch Neurol; 2008 Feb; 65(2):193-8. PubMed ID: 18268187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Dyskinesia-hyperpyrexia syndrome in a patient with Parkinson's disease: a case report].
    Taguchi S; Niwa J; Ibi T; Doyu M
    Rinsho Shinkeigaku; 2015; 55(3):182-4. PubMed ID: 25786757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease.
    Kumru H; Iranzo A; Carrasco E; Valldeoriola F; Marti MJ; Santamaria J; Tolosa E
    Sleep; 2008 Oct; 31(10):1418-21. PubMed ID: 18853939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
    Pahwa R; Tanner CM; Hauser RA; Isaacson SH; Nausieda PA; Truong DD; Agarwal P; Hull KL; Lyons KE; Johnson R; Stempien MJ
    JAMA Neurol; 2017 Aug; 74(8):941-949. PubMed ID: 28604926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
    Pinter MM; Pogarell O; Oertel WH
    J Neurol Neurosurg Psychiatry; 1999 Apr; 66(4):436-41. PubMed ID: 10201413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
    Hauser RA; Schapira AH; Rascol O; Barone P; Mizuno Y; Salin L; Haaksma M; Juhel N; Poewe W
    Mov Disord; 2010 Nov; 25(15):2542-9. PubMed ID: 20669317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.
    Haycox A; Armand C; Murteira S; Cochran J; François C
    Drugs Aging; 2009; 26(9):791-801. PubMed ID: 19728752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Caffeine consumption and risk of dyskinesia in CALM-PD.
    Wills AM; Eberly S; Tennis M; Lang AE; Messing S; Togasaki D; Tanner CM; Kamp C; Chen JF; Oakes D; McDermott MP; Schwarzschild MA;
    Mov Disord; 2013 Mar; 28(3):380-3. PubMed ID: 23339054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heart valve abnormalities in Parkinson's disease treated with dopamine agonists.
    Bares M; Rektorová I; Krajcovicová L; Rektor I
    J Neurol; 2008 Oct; 255(10):1596; author reply 1597. PubMed ID: 18758889
    [No Abstract]   [Full Text] [Related]  

  • 34. Pramipexole-induced antecollis in Parkinson's disease.
    Suzuki M; Hirai T; Ito Y; Sakamoto T; Oka H; Kurita A; Inoue K
    J Neurol Sci; 2008 Jan; 264(1-2):195-7. PubMed ID: 17826796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects.
    Micallef J; Rey M; Eusebio A; Audebert C; Rouby F; Jouve E; Tardieu S; Blin O
    Br J Clin Pharmacol; 2009 Mar; 67(3):333-40. PubMed ID: 19220275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
    Lyons KE; Pahwa R
    Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M; Markham A
    Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
    Etminan M; Samii A; Takkouche B; Rochon PA
    Drug Saf; 2001; 24(11):863-8. PubMed ID: 11665873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.